1 of 1
Story summary
- WHO said enrollment for PARTNERS trial in Democratic Republic of the Congo July 2, 2026.
- The trial, led by the Institut National de Recherche Biomédicale and coordinated by Belgium, Oxford and Africa CDC, targets Bundibugyo strain, which Monica Gandhi of UCSF says lacks vaccines or therapy.
- The study will test antibody MBP134 and antiviral remdesivir, alone and together, for survival benefit under a protocol based on data and outbreak outcomes.
